|
AU2016204688A1
|
|
Milnacipran for the long-term treatment of fibromyalgia syndrome
|
|
AU2013205113A1
|
|
Milnacipran for the long-term treatment of fibromyalgia syndrome
|
|
US2011189777A1
|
|
Methods and compositions for improved diagnostic assays
|
|
EP2347259A2
|
|
Method for diagnosis and monitoring of disease activity and response to treatment in systemic lupus erythematosus (sle) and other autoimmune diseases
|
|
WO2009132132A2
|
|
Prediction of an individual's risk of developing rheumatoid arthritis
|
|
WO2008157094A1
|
|
Improving the tolerability of mirtazapine and a second active by using them in combination
|
|
TW200911225A
|
|
Methods for improving physical function in fibromyalgia
|
|
AU2008201910A1
|
|
Prevention and treatment of functional somatic disorders, including stress-related disorders
|
|
EP2146576A1
|
|
Treatment of down syndrome with benzodiazepine receptor antagonists
|
|
TW200814989A
|
|
Milnacipran for the treatment of cognitive dysfunction associated with fibromyalgia
|
|
US2008058317A1
|
|
Milnacipran for the treatment of fatigue associated with fibromyalgia syndrome
|
|
TW200814990A
|
|
Milnacipran for the treatment of fatigue associated with fibromyalgia syndrome
|
|
US2008058318A1
|
|
Milnacipran for the treatment of cognitive dysfunction associated with fibromyalgia
|
|
MX2008009992A
|
|
Compositions comprising a bisphosphonate and an antifolate.
|
|
US2007123555A1
|
|
Prevention and treatment of hearing disorders
|
|
US2007072946A1
|
|
Milnacipran for the long-term treatment of fibromyalgia syndrome
|
|
US2007021352A1
|
|
Prevention and treatment of hearing disorders
|
|
US2006122127A1
|
|
Methods for reducing the side effects associated with mirtzapine treatment
|
|
US2006039866A1
|
|
Method for treating sleep-related breathing disorders
|
|
WO2004105690A2
|
|
Treatment of chronic pain associated with drug or radiation therapy
|
